Perrigo Company (PRGO) - NYSE
  • Mon, Jul. 18, 10:15 AM
    • The FDA approves Perrigo's (PRGO -0.6%) generic version of Zegerid OTC (omeprazole and sodium bicarbonate capsules, 20 mg/1100 mg) for the treatment of frequent heartburn. The product will be sold as a private label brand for retailers.
    • The U.S. market is ~$27M.
    | Mon, Jul. 18, 10:15 AM | 1 Comment
  • Sun, Jul. 3, 2:50 PM
    • via Barclays:
    • "Although stocks in the U.S. and Europe have partially bounced back from the sharp selloff sparked by the U.K. referendum result, risks remain prevalent. [Analyst] Keith Parker foresees further equity downside alongside a prolonged market bottoming process, during which positioning is likely to turn much more defensive at active managers.
    • "With this in mind, our stock screen this week highlights Overweight-rated stocks that screen defensively based on sector and equity beta but are also expected to generate superior ROE and free cash flows in FY1.
    • "Our screen considers the following factors: i) Large-cap (US $5 billion+) stock in the consumer staples, utilities, telecom or healthcare sectors. ii) Adjusted beta less than 1.0. iii) Rated Overweight by Barclays equity research. iv) 15%+ ROE and 4.5%+ FCF yield expected in FY1, based on Barclays estimates."
    • The stocks: Aetna (NYSE:AET), BT Group plc (NYSE:BT), Cardinal Health (NYSE:CAH), Coloplast (OTC:CLPBF, OTCPK:CLPBY), CVS (NYSE:CVS), Estee Lauder (NYSE:EL), Express Scripts (NASDAQ:ESRX), Glanbia (OTC:GLAPF, OTCPK:GLAPY), Grifols (NASDAQ:GRFS), Imperial Brands (OTCQX:IMBBY, OTCQX:ITYBF), Johnson & Johnson (NYSE:JNJ), Ahold (OTCQX:AHONY, OTCQX:AHODF, OTCQX:AHOND), LabCorp (NYSE:LH), Perrigo (NYSE:PRGO), Telus (NYSE:TU), Unilever (UL, UN), UnitedHealth Group (NYSE:UNH)
    • See full table here.
    | Sun, Jul. 3, 2:50 PM | 14 Comments
  • Fri, Jun. 24, 7:01 AM
    • Cerner (NASDAQ:CERN) upgraded to Buy from Neutral with $65 (14% upside) price target by SunTrust Robinson.
    • Catalent (NYSE:CTLT) upgraded to Outperform from Market Perform with a $26 (midpoint)(10% upside) price target by Wells Fargo. Upgraded to Buy from Neutral by Bank of America.
    • Centene (NYSE:CNC) upgraded to Overweight from Equal Weight by Barclays. Price target raised to $82 (17% upside) from $76.
    • Valeant Pharmaceuticals (NYSE:VRX) downgraded to Neutral from Overweight by JPMorgan. Price target lowered to $35 (57% upside) from $50.
    • AveXis (NASDAQ:AVXS) downgraded to Hold from Buy by Jefferies. Price target lowered to $39 (3% downside risk) from $42.
    • Surgical Care Affiliates (NASDAQ:SCAI) downgraded to Neutral from Buy by JPMorgan. Price target maintained at $48 (3% upside).
    • ACADIA Pharmaceuticals (NASDAQ:ACAD) downgraded to Neutral from Buy by Bank of America.
    • Express Scripts Holdings (NASDAQ:ESRX) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target raised to $70 (9% downside risk) from $67.
    • Perrigo (NYSE:PRGO) downgraded to Hold from Buy by Argus Research.
    • CVS Health (NYSE:CVS) downgraded to Equal Weight from Overweight by Morgan Stanley. Price target lowered to $104 (11% upside) from $111.
    | Fri, Jun. 24, 7:01 AM | 19 Comments
  • Wed, Jun. 15, 12:45 PM
    • According to an unnamed source, Perrigo (PRGO -4.2%) is close to being acquired for $20B by a UK-based company (Glaxo or AstraZeneca?).
    • Although up almost 30% since mid-May, Perrigo is still down almost 50% from about a year ago.
    • (GSK +0.3%)(AZN +0.9%)
    | Wed, Jun. 15, 12:45 PM | 16 Comments
  • Fri, May 27, 5:39 PM
    | Fri, May 27, 5:39 PM
  • Tue, May 17, 8:15 AM
    • Perrigo (NYSE:PRGO) is down 3% premarket on average volume in response to its announcement that it adjusted its Q1 GAAP net loss downward from ($133.1M) to ($335M) and its GAAP loss per share to ($2.34) from ($0.93). Non-GAAP results and 2016 guidance remain unchanged.
    | Tue, May 17, 8:15 AM | 4 Comments
  • Thu, May 12, 9:14 AM
    • Perrigo (PRGO) Q1 results: Revenues: $1,383.2M (+31.8%); Operating Expense: $354.3M (+98.5%); Operating Loss: ($303.8M) (-252.5%); Net Loss: ($133.1M) (-40.3%); Loss Per Share: ($0.93) (-38.8%); Non-GAAP EPS: $1.75 (-5.4%); Quick Assets: $588.9M (+41.0%); CF Ops: $170.3M (-36.5%).
    • 2016 Guidance: Reported EPS: $2.44 - 2.84; Adjusted EPS: $8.20 - 8.60.
    | Thu, May 12, 9:14 AM | 3 Comments
  • Thu, May 12, 6:01 AM
    • Perrigo (NYSE:PRGO): Q1 EPS of $1.75 in-line.
    • Revenue of $1.38B (+31.4% Y/Y) beats by $30M.
    • Press Release
    | Thu, May 12, 6:01 AM | 1 Comment
  • Wed, May 11, 5:30 PM
    | Wed, May 11, 5:30 PM | 3 Comments
  • Mon, May 2, 9:48 AM
    • The FDA approves Perrigo's (PRGO -0.5%) generic version of Valeant Pharmaceuticals' (VRX -7.1%) BenzaClin Pump Topical Gel for the treatment of acne vulgaris. The U.S. market is ~$80M.
    • Product shipments have already begun.
    | Mon, May 2, 9:48 AM | 17 Comments
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Tue, Apr. 26, 8:26 AM
    | Tue, Apr. 26, 8:26 AM | 3 Comments
  • Mon, Apr. 25, 12:47 PM
    | Mon, Apr. 25, 12:47 PM | 20 Comments
  • Mon, Apr. 25, 10:44 AM
    • On a preliminary basis, Perrigo (PRGO -12.3%) expects Q1 non-GAAP EPS of $1.71 - 1.77 on revenues of $1.33B - 1.35B. On a GAAP basis, EPS should be $0.61 - 0.67. Full results should be released shortly.
    | Mon, Apr. 25, 10:44 AM | 2 Comments
  • Mon, Apr. 25, 9:17 AM
    | Mon, Apr. 25, 9:17 AM
  • Mon, Apr. 25, 8:24 AM
    • Perrigo (NYSE:PRGO) names President John Hendrickson as CEO. The board decided to waive the non-compete clause in former chief Joseph Papa's contract and not contest his departure to Valeant Pharmaceuticals (NYSE:VRX).
    • Shares are off 11% premarket  on robust volume.  VRX is up 2%.
    • Update: Valeant formerly announces the hiring of Mr. Papa.
    | Mon, Apr. 25, 8:24 AM | 36 Comments
Company Description
Perrigo Co. Plc engages in the production of over-the-counter consumer goods and specialty pharmaceutical products. It operates through the following segments: Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals, and Specialty Sciences. The CHC segment... More
Sector: Healthcare
Industry: Drug Related Products
Country: United States